|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
20.100 +0.420 (+2.134%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 575,167,877 | -1.598% | 584,507,930 | 596,569,565 | 552,147,550 | 521,051,235 |
| Cost of Sales | (533,495,864) | -1.251% | (540,252,540) | (548,057,887) | (504,713,490) | (477,000,627) |
| Gross Profit | 41,672,013 | -5.837% | 44,255,390 | 48,511,678 | 47,434,060 | 44,050,608 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (598,478) | |
| Profit / (Loss) on Disposal | (1,041,018) | -34.199% | (1,582,079) | (2,067,764) | (1,936,170) | (1,130,821) | |
| Other Non-operating Items | (476,592) | -54.981% | (1,058,658) | 625,967 | 82,278 | (375,813) | |
| Share of Results of Asso. & JCEs | 1,232,907 | 2.794% | 1,199,396 | 1,107,349 | 1,067,067 | 1,069,868 | |
| Profit / (Loss) before Taxation | 14,799,627 | 5.705% | 14,000,899 | 19,512,137 | 18,563,819 | 17,003,162 | |
| Taxation | (3,965,193) | 10.843% | (3,577,305) | (4,502,309) | (4,218,377) | (3,938,389) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,679,340) | 9.053% | (3,373,911) | (5,956,068) | (5,819,787) | (5,306,127) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 7,155,094 | 1.495% | 7,049,683 | 9,053,760 | 8,525,655 | 7,758,646 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,994,912 | -14.317% | 2,328,242 | 2,430,374 | 3,189,992 | 3,402,869 |
| Depreciation & Amortisation | 4,289,055 | -9.393% | 4,733,692 | 4,430,248 | 4,165,019 | 3,922,058 |
| Directors' Emoluments | -- | -- | 7,273 | 14,991 | 14,516 | 15,277 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 229.000 | 1.327% | 226.000 | 290.000 | 273.000 | 249.000 |
| DPS (cts) | 69.000 | -- | 68.000 | 87.000 | 82.000 | 75.000 |
| Dividend Payout Ratio (%) | 30.131% | -- | 30.088% | 30.000% | 30.037% | 30.120% |
| Cash flow per share ($) | -- | -- | 3.700 | 5.510 | 6.726 | 2.983 |
| NBV per share ($) | 26.902 | -- | 25.278 | 23.900 | 21.812 | 19.831 |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 7,155,094 |
| %Change | 1.495% |
| EPS / (LPS) | RMB 2.290 |
| NBV Per Share (¥) | RMB 26.902 |